HKD 7.83
(-6.23%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 134.28 Million CNY | -6.2% |
2022 | 143.16 Million CNY | 20.83% |
2021 | 118.48 Million CNY | -93.31% |
2020 | 1.77 Billion CNY | 127.26% |
2019 | 779.26 Million CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 120.16 Million CNY | 0.0% |
2024 Q1 | 120.16 Million CNY | -10.51% |
2023 FY | 134.28 Million CNY | -6.2% |
2023 Q2 | 115.86 Million CNY | 0.0% |
2023 Q1 | 115.86 Million CNY | -19.07% |
2023 Q4 | 134.28 Million CNY | 0.0% |
2023 Q3 | 134.28 Million CNY | 15.89% |
2022 Q2 | 118.45 Million CNY | 0.0% |
2022 Q1 | 118.45 Million CNY | -0.02% |
2022 FY | 143.16 Million CNY | 20.83% |
2022 Q4 | 143.16 Million CNY | 0.0% |
2022 Q3 | 143.16 Million CNY | 20.86% |
2021 Q2 | - CNY | -100.0% |
2021 FY | 118.48 Million CNY | -93.31% |
2021 Q1 | 2.64 Billion CNY | 0.0% |
2021 Q4 | 118.48 Million CNY | 0.0% |
2021 Q3 | 118.48 Million CNY | 0.0% |
2020 FY | 1.77 Billion CNY | 127.26% |
2020 Q1 | - CNY | 0.0% |
2019 FY | 779.26 Million CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | 12.131% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 98.098% |